Klinische Studie zum Nectero EAST System (stAAAble)
Randomisierte kontrollierte klinische Studie (RCT) des Nectero EAST-Systems für kleine bis mittelgroße abdominale Aortenaneurysmen (AAA) Stabilisierung: Bewertung der Wirksamkeit.
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Charlene Knape
- Telefonnummer: 866-755-4744
- E-Mail: cknape@necteromedical.com
Studieren Sie die Kontaktsicherung
- Name: Tracy Roberts
- Telefonnummer: (303)3964603
- E-Mail: troberts@necteromedical.com
Studienorte
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekrutierung
- Prince of Wales Private Hospital- POW Vascular Institute
-
Hauptermittler:
- Ramon Varcoe
-
Kontakt:
- Jade Goh
- Telefonnummer: 04 87 369 396
- E-Mail: pow.vascular.institute@gmail.com
-
-
-
-
-
Auckland, Neuseeland, 1023
- Rekrutierung
- Auckland City Hospital
-
Kontakt:
- Cynthia Corne
- Telefonnummer: 21505 +64 9 307 4949
- E-Mail: CorneC@adhb.govt.nz
-
Hauptermittler:
- Andrew Holden, A/Prof
-
-
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85258
- Rekrutierung
- Honor Health Scottsdale Shea Medical Center
-
Hauptermittler:
- Hasan Aldailami, MD
-
Kontakt:
- HonorHealth Cardiovascular Research
- Telefonnummer: 480-323-1046
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Aktiv, nicht rekrutierend
- University of Colorado
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- Medstar Washington Hospital Center
-
Hauptermittler:
- Steven Abramowitz, MD
-
Kontakt:
- Kassaye Sesaba, MD
- Telefonnummer: 202-877-7452
- E-Mail: Kassaye.T.Sesaba@medstar.net
-
Kontakt:
- Suman Singh, MD
- Telefonnummer: (202) 877-8475
- E-Mail: Suman.Singh@Medstar.net
-
-
Florida
-
Delray Beach, Florida, Vereinigte Staaten, 33446
- Rekrutierung
- Prime Vascular Institute
-
Hauptermittler:
- Joseph Ricotta, MD
-
Kontakt:
- Jordan Sprechman
- Telefonnummer: 561-495-3145
- E-Mail: Jordan.Sprechman@tenethealth.com
-
Kontakt:
- Alexia Medick
- E-Mail: Alexia.Medick@tenethealth.com
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Rekrutierung
- Medical College of Georgia
-
Hauptermittler:
- William Jordan, MD
-
Kontakt:
- Natasha Flores
- E-Mail: nflores@augusta.edu
-
Kontakt:
- Candelario Laserna
- Telefonnummer: 706-721-2199
- E-Mail: calaserna@augusta.edu
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago
-
Kontakt:
- MacKenton Johnson
- Telefonnummer: 773-795-3639
- E-Mail: mackenton@bsd.uchicago.edu
-
Hauptermittler:
- Ross Milner, MD
-
Elk Grove, Illinois, Vereinigte Staaten, 60007
- Noch keine Rekrutierung
- Ascension Alexian Brothers
-
Hauptermittler:
- Jack Chamberlin, MD
-
-
Maine
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- MaineMed Vascular Surgery
-
Hauptermittler:
- Kristina Giles, MD
-
Kontakt:
- Kathryn Ackermann
- E-Mail: kathryn.ackermann@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
Hauptermittler:
- Nikolaos Zacharias, MD
-
Kontakt:
- Bonnie Chen
- E-Mail: BCHEN13@mgh.harvard.edu
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Beth Israel Deaconess Medical Center
-
Hauptermittler:
- Marc Schermerhorn, MD
-
Kontakt:
- Monica Goyal
- Telefonnummer: 617-632-7534
- E-Mail: mgoyal@bidmc.harvard.edu
-
Kontakt:
- Fernando Moreno
- E-Mail: fmoreno@bidmc.harvard.edu
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- University of Massachusetts
-
Kontakt:
- Shauneen Valliere
- E-Mail: shauneen.valliere@umassmed.edu
-
Hauptermittler:
- Andres Schanzer, MD
-
-
Michigan
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Beaumont Health
-
Hauptermittler:
- Graham Long, MD
-
Kontakt:
- Lisa Bliss
- E-Mail: lisa.bliss@corewellhealth.org
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Hauptermittler:
- Luis Sanchez, MD
-
Kontakt:
- Briana K Langrehr, BSN
- E-Mail: briana.l@wustl.edu
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Hauptermittler:
- Jonathan Thompson, MD
-
Kontakt:
- Jarod Phillips
- E-Mail: jarphillips@unmc.edu
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03766
- Rekrutierung
- Dartmouth Hitchcock Medical Center
-
Hauptermittler:
- Rebecca Scully, MD
-
Kontakt:
- Pauline Sirrell
- E-Mail: pauline.sirrell@hitchcock.org
-
-
New York
-
Rochester, New York, Vereinigte Staaten, 14642
- Rekrutierung
- University of Rochester
-
Kontakt:
- Mary Bourret
- E-Mail: Mary_Bourret@URMC.Rochester.edu
-
Hauptermittler:
- Doran Mix, MD
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Noch keine Rekrutierung
- Stony Brook Medicine
-
Hauptermittler:
- Rabih Chaer, MD
-
Kontakt:
- Daria Shavarina
- E-Mail: Daria.Shavarina@stonybrookmedicine.edu
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Chandler Long, MD
-
Kontakt:
- Ellen Burkett
- Telefonnummer: (919)681-1878
- E-Mail: ellen.jones@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Rekrutierung
- The Christ Hospital
-
Kontakt:
- Jamie Elkins
- E-Mail: Jamie.Elkins@thechristhospital.com
-
Hauptermittler:
- Geoff Answini, MD
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- University Hospitals Cleveland
-
Hauptermittler:
- Jae Cho, MD
-
Kontakt:
- Amy Kluge
- E-Mail: Amy.Kluge@UHhospitals.org
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic
-
Hauptermittler:
- Francis Caputo, MD
-
Kontakt:
- Laurie Ann Moennich
- E-Mail: MOENNIL@ccf.org
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The Ohio State University Wexner Medical Center
-
Kontakt:
- Subh Das
- Telefonnummer: 614-366-6596
- E-Mail: subhashish.das@osumc.edu
-
Hauptermittler:
- Kristine Orion, MD
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Rekrutierung
- Ohio Health Riverside
-
Hauptermittler:
- Joseph Campbell, MD
-
Kontakt:
- Regan Moran
- E-Mail: Regan.Moran@ohiohealth.com
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74104
- Rekrutierung
- Oklahoma Heart Institute
-
Hauptermittler:
- Julia Chen, MD
-
Kontakt:
- Tia Whitaker
- E-Mail: Tia.Whitaker@hillcrest.com
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Portland VA Medical Center
-
Hauptermittler:
- Matthew Koopmann, MD
-
Kontakt:
- Rachel Nelson
- E-Mail: Rachel.Nelson1@va.gov
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- Rekrutierung
- St. Luke's University Health Network
-
Hauptermittler:
- Sharvil Sheth, MD
-
Kontakt:
- Jena Hagerty
- Telefonnummer: 484-658-4982
- E-Mail: Jena.Hagerty@sluhn.org
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Hospital of the University of Pennsylvania
-
Kontakt:
- Carolina Reyes
- Telefonnummer: 215-615-8036
- E-Mail: carolina.reyes1@pennmedicine.upenn.edu
-
Hauptermittler:
- Grace Wang, MD
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Jefferson Clinical Research Institute
-
Kontakt:
- Jona Shperdheja
- E-Mail: Jona.Shperdheja@jefferson.edu
-
Hauptermittler:
- Michael Nooromid, MD
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- Rekrutierung
- University of Pittsburgh Medical Center
-
Kontakt:
- Judith Brimmeier
- E-Mail: brimmeierja@upmc.edu
-
Hauptermittler:
- Raymond Eid, MD
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health
-
Hauptermittler:
- Mark P Androes, MD
-
Kontakt:
- Nikita Kasinger
- E-Mail: Nikita.Kasinger@PrismaHealth.org
-
Kontakt:
- Maggie Salle
- E-Mail: Margaret.Salle@PrismaHealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57108
- Rekrutierung
- North Central Heart - A Division of Avera Heart Hospital
-
Hauptermittler:
- Michael Bacharach, MD
-
Kontakt:
- Patty Eisenbraun, RN
- Telefonnummer: 605-977-5336
- E-Mail: peisenbraun@ncheart.com
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University Medical Center
-
Hauptermittler:
- John Curci, MD
-
Kontakt:
- Celia Nunez
- E-Mail: celia.m.nunez@vumc.org
-
Kontakt:
- Jennifer Scott
- E-Mail: jennifer.scott@vumc.org
-
Nashville, Tennessee, Vereinigte Staaten, 37212
- Noch keine Rekrutierung
- VA Tennessee Valley Healthcare System
-
Hauptermittler:
- John Curci, MD
-
Kontakt:
- Sohpia Miner
- E-Mail: Sophia.Miner@va.gov
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77004
- Rekrutierung
- Houston Healthcare
-
Hauptermittler:
- Kristofer Charlton-Ouw, MD
-
Kontakt:
- Swathi Potla
- E-Mail: swathi.potla@hcahealthcare.com
-
Plano, Texas, Vereinigte Staaten, 75093
- Rekrutierung
- Baylor Scott & White Medical Center
-
Hauptermittler:
- William Shutze, MD
-
Kontakt:
- Saba Arianpour
- E-Mail: Saba.Arianpour@BSWHealth.org
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- Rekrutierung
- University of Utah Hospital
-
Kontakt:
- Julie Hales
- E-Mail: Julie.Hales@hsc.utah.edu
-
Hauptermittler:
- Cali Johnson, MD
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Inova Fairfax Medical Campus Inova Health Systems
-
Kontakt:
- Bhruga Shah
- E-Mail: Bhruga.shah@inova.org
-
Hauptermittler:
- Kendal Endicott, MD
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Rekrutierung
- Sentara Health
-
Hauptermittler:
- David Dexter, MD
-
Kontakt:
- Angela Zahn
- E-Mail: AXZAHN@sentara.com
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- University of Washington at Harborview Medical Center
-
Kontakt:
- Allison Larimore
- E-Mail: alari@uw.edu
-
Hauptermittler:
- Benjamin Starnes, MD
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Rekrutierung
- Bellin Memorial Hospital
-
Hauptermittler:
- Jason Ricci, MD
-
Kontakt:
- Katie Guilliams
- E-Mail: Katherine.Guilliams@emplifyhealth.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
- Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
- Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
- Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
- Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
- Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
- Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
- Subject has > three-year life expectancy.
- Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years) and blood draws.
Exclusion Criteria:
- Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
- Subject has a symptomatic infrarenal abdominal aortic aneurysm.
- Subject has a mycotic or infected aneurysm.
- Subject has current vascular injury due to trauma.
- Subject's aneurysm is thoracic, suprarenal or juxtarenal.
- Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
- Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
- Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
- Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.
- Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
- Subject has undergone other major surgery within the 30 days prior to enrollment.
- Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
- Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG).
- Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
- Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
- Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.
- Subject has active systemic infection.
- Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
- Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2.
- Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB that is our of normal range for the evaluating laboratory.
- Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
- Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
- Subjects with saccular AAA.
- Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
- Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.
- Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy.
- Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.
- Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3).
- Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.
- Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Treatment Arm
Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years. Intervention: Drug: Stabilizer |
Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug. |
|
Kein Eingriff: Control Arm
Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Primary Endpoint
Zeitfenster: 24 months
|
The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm). |
24 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Growth
Zeitfenster: 24 months
|
The growth over time in aneurysm diameter based on CT core laboratory readings. |
24 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Daniel Clair, MD, Vanderbilt University Medical Center
- Hauptermittler: Grace Wang, MD, University of Pennsylvania
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- EAST002
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .